Osimertinib after Chemoradiotherapy in Stage III EGFR-Mutated NSCLC.

doi:10.1056/NEJMoa2402614

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Community

Back to search

Article

Osimertinib after Chemoradiotherapy in Stage III EGFR-Mutated NSCLC.

The New England journal of medicine - 15 Aug 2024

Lu Shun, Kato Terufumi, Dong Xiaorong, Ahn Myung-Ju, Quang Le-Van, Soparattanapaisarn Nopadol, Inoue Takako, Wang Chih-Liang, Huang Meijuan, Yang James Chih-Hsin, Cobo Manuel, Özgüroğlu Mustafa, Casarini Ignacio, Khiem Dang-Van, Sriuranpong Virote, Cronemberger Eduardo, Takahashi Toshiaki, Runglodvatana Yotsawaj, Chen Ming, Huang Xiangning, Grainger Ellie, Ghiorghiu Dana, van der Gronde Toon, Ramalingam Suresh S

Abstract excerpt

BACKGROUND: Osimertinib is a recommended treatment for advanced non-small-cell lung cancer (NSCLC) with an epidermal growth factor receptor (EGFR) mutation and as adjuvant treatment for resected EGFR-mutated NSCLC. EGFR tyrosine kinase inhibitors have shown preliminary efficacy in unresectable stage III EGFR-mutated NSCLC. METHODS: In this phase 3, double-blind, placebo-controlled trial, we randomly assigned...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Acrylamides

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Aniline Compounds

Share to Chemoradiotherapy

Share to Double-Blind Method

Share to Indoles

Share to Progression-Free Survival

Share to Pyrimidines

Share to Tyrosine Kinase Inhibitors

Source

Open in PubMed

Identifiers

PMID: 38828946
DOI: 10.1056/NEJMoa2402614

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 5 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Osimertinib after Chemoradiotherapy in Stage III EGFR-Mutated NSCLC.PMID 38828946Read ↗

Osimertinib after definitive chemoradiotherapy in patients with unresectable stage III EGFR-mutated NSCLC: LAURA China cohort.Semantic proximity Read ↗

Osimertinib in Resected EGFR-Mutated Non-Small-Cell Lung Cancer.Semantic proximity Read ↗

Osimertinib after definitive CRT in unresectable stage III EGFR-mutated NSCLC: safety outcomes from the phase III LAURA study.Semantic proximity Read ↗

Overall Survival with Osimertinib in Resected EGFR-Mutated NSCLC.Semantic proximity Read ↗

Adjuvant Osimertinib for Resected EGFR-Mutated Stage IB-IIIA Non-Small-Cell Lung Cancer: Updated Results From the Phase III Randomized ADAURA Trial.Semantic proximity Read ↗

Overall Survival with Osimertinib in Untreated, EGFR-Mutated Advanced NSCLC.Semantic proximity Read ↗

Survival with Osimertinib plus Chemotherapy in EGFR-Mutated Advanced NSCLC.Semantic proximity Read ↗

Efficacy and safety of osimertinib for patients with EGFR-mutated NSCLC: a systematic review and meta-analysis of randomized controlled studies.Semantic proximity Read ↗

Osimertinib: A Review in Previously Untreated, EGFR Mutation-Positive, Advanced NSCLC.Semantic proximity Read ↗

Osimertinib: A Review in Completely Resected, Early-Stage, EGFR Mutation-Positive NSCLC.Semantic proximity Read ↗

Osimertinib Maintenance After Definitive Chemoradiation in Patients With Unresectable EGFR Mutation Positive Stage III Non-small-cell Lung Cancer: LAURA Trial in Progress.Semantic proximity Read ↗

Overall survival in stage IV EGFR mutation‑positive NSCLC: Comparing first‑, second‑ and third‑generation EGFR‑TKIs (Review).Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.